Literature DB >> 8187796

Comparative activity of the new fluoroquinolone Bay y3118 against 177 penicillin susceptible and resistant pneumococci.

S K Spangler1, M R Jacobs, P C Appelbaum.   

Abstract

The activity of a new fluoroquinolone, Bay y3118, was evaluated in comparison to three quinolones (ciprofloxacin, ofloxacin, lomefloxacin) and four broad-spectrum oral cephalosporins (cefpodoxime, cefuroxime, cefaclor, cefixime) against 49 penicillin-susceptible pneumococci, 77 pneumococci with intermediate resistance and 51 penicillin-resistant pneumococci. Quinolone activity was not affected by the penicillin susceptibility status of the organisms. Bay y3118 was very active against all strains, with an MIC90 of 0.015 microgram/ml. Other quinolones were less active, with MIC90s of 4 micrograms/ml (ciprofloxacin and ofloxacin) and 8 micrograms/ml (lomefloxacin). Cephalosporin MICs rose parallel to those of penicillin. Cefuroxime and cefpodoxime were the most active cephalosporins, with MIC90s for strains showing susceptibility, intermediate resistance and resistance of 0.125-0.25, 2-4 and 4 micrograms/ml, respectively. Cefaclor and cefixime were less active, with corresponding MIC90s of 1-2, 8-16 and > 16 micrograms/ml, respectively.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8187796     DOI: 10.1007/bf01992176

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

Review 1.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

2.  Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990).

Authors:  J Liñares; R Pallares; T Alonso; J L Perez; J Ayats; F Gudiol; P F Viladrich; R Martin
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

Review 3.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

4.  The in-vitro activity of PD127,391, a new quinolone.

Authors:  A King; C Boothman; I Phillips
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

5.  Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.

Authors:  S K Spangler; M R Jacobs; G A Pankuch; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1993-02       Impact factor: 5.790

6.  In vitro evaluation of BAY Y3118, a new full-spectrum fluoroquinolone.

Authors:  K D Bremm; U Petersen; K G Metzger; R Endermann
Journal:  Chemotherapy       Date:  1992       Impact factor: 2.544

7.  In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.

Authors:  N X Chin; A Novelli; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

8.  Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

9.  Screening for cephalosporin-resistant Streptococcus pneumoniae with the Kirby-Bauer disk susceptibility test.

Authors:  I R Friedland; S Shelton; G H McCracken
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

10.  In-vitro activity of tosufloxacin, a new quinolone antibacterial agent.

Authors:  M A Cooper; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1992-06       Impact factor: 5.790

View more
  5 in total

1.  Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

2.  Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae.

Authors:  Y S Kim; Q Liu; L L Chow; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides.

Authors:  S Hunt Gerardo; D M Citron; M C Claros; E J Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

4.  Moxifloxacin in the therapy of experimental pneumococcal meningitis.

Authors:  H Schmidt; A Dalhoff; K Stuertz; F Trostdorf; V Chen; O Schneider; C Kohlsdorfer; W Brück; R Nau
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

5.  Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits.

Authors:  R Nau; T Schmidt; K Kaye; J L Froula; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.